Inhalation Sciences’ launch of the XposeALI[®] in vitro module with microperfusion
(Stockholm, Sweden, 13 January 2025) Inhalation Sciences (ISAB) announces its plans to launch the company’s XposeALI® in vitro exposure module, now with microperfusion. The development work was undertaken in 2024 with the final testing and validation being performed in a study co-financed with one of the company’s longstanding global pharmaceutical customers.
By adding the option of microperfusion to the XposeALI system, the mode-of-action of inhaled substances in the lungs can now be simulated in vitro with higher relevance. The unique capability of the XposeALI system to deliver various aerosols from the company’s multi-modular aerosol platform PreciseInhale® to airway cell cultures is already well-established and proven. The addition of microperfusion medium instead of static volume of nutrient medium to sustain the cells allows the full physiology of the air-and blood barrier to be simulated. The local dose of a soluble drug in the cell culture consists both of aerosol deposition/dissolution of drug on the cells followed by drug removal from the cells with microperfusion. Once achieved, drug permeability can be measured in vitro in a manner that simulates in vivo lung pharmacokinetics.
With XposeALI microperfusion, ISAB will access the in vitro biological market for inhaled drugs which has gained renewed interest, particularly after the COVID-19 pandemic and the significant growth of innovative biologics treatments. There are over 300 biologics compounds in development using inhalation as the route of administration. The cost of biological drugs is much higher than for small molecular drugs, so the low substance consumption of the platform is here an even greater advantage. The global market for biological therapeutics is growing with estimates of the market surpassing US $4 billion by 2025.[1]
CEO Manoush Masarrat comments: “I am very proud of the development work for XposeALI in 2024 and looking forward to seeing the result of the upcoming study with our customer. Together with the DissolvIt module for generics and with XposeALI microperfusion for biologics, we are in a unique position to serve our customers with innovative service solutions in In vitro R&D Inhalation.”
For more information about Inhalation Sciences, please contact:
Manoush Masarrat, CEO
E-mail: Manoush.masarrat@inhalation.se
Mobile: +46 (0)73 628 9153
About Inhalation Sciences Sweden AB (publ)
Inhalation Sciences Sweden AB (publ) develops and commercializes world-leading instruments and services for research into inhalation. The company’s patented lab instruments PreciseInhale® and DissolvIt® enable researchers in the pharma industry to make drug pipeline decisions at an early stage, saving time and resources for R&D departments, and enables researchers in academic institutions to define how aerosols and small particles impact our lungs, and so our health, when being inhaled.